Search clinical trials for: Endothelial Growth Factors

Total 33249 results

Janssen Research & Development, LLC

Active, not recruiting

A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant (AURIGA)

Multiple Myeloma

United States, Canada
Abramson Cancer Center of the University of Pennsylvania

Completed

Maintenance Lenalidomide in Lymphoma

Lymphoma

United States
Kenneth Ain
Celgene Corporation

Completed

REVLIMID® (Lenalidomide) for Therapy of Radioiodine-Unresponsive Papillary and Follicular Thyroid Carcinomas

Thyroid Neoplasms

United States
Brown University
Memorial Hospital of Rhode Island; Roger Williams Medical Center

Completed

Lenalidomide for Advanced Hepatocellular Cancer:A Phase II Trial

Liver Cancer

United States
Celgene

Completed

A Non-interventional, Observational Post-marketing Registry of Patients Treated With Revlimid (Lenalidomide) in Taiwan

Multiple Myeloma

Taiwan
Celgene

Completed

MORE - Monitoring Revlimid - Collecting of Patient Information From Myelodysplastic Syndrome (MDS) Italian National Registry (MORE)

Myelodysplastic Syndrome

Italy
Celgene

Completed

Study of the Safety and Efficacy of CC-5013 Treatment For Patients With Myelodysplastic Syndrome

Myelodysplastic Syndrome

United States
Associazione Qol-one

Terminated

Efficacy of Eltrombopag Plus Lenalidomide Combination Therapy in Patients With IPSS Low and Intermediate-risk Myelodysplastic Syndrome With Isolated del5q

Myelodysplastic Syndromes

France, Italy, Greece
M.D. Anderson Cancer Center
Celgene

Completed

Lenalidomide as Initial Treatment of Patients With Chronic Lymphocytic Leukemia (CLL) Age 65 and Older

Leukemia | Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | CLL

United States
Groupe Francophone des Myelodysplasies
Celgene Corporation

Unknown

A Study of the Efficacy and Safety of Lenalidomide Combined to Escalating Doses of Chemotherapy in Intermediate-2-or High Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) With Del 5q (GFM-Chimio-Rev)

Acute Myeloid Leukemia | Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome

France
Arbeitsgemeinschaft medikamentoese Tumortherapie
Celgene Corporation

Unknown

Lenalidomide in Patients With Chronic Myelomonocytic Leukemia

Chronic Myelomonocytic Leukemia

Austria
Washington University School of Medicine

Completed

Lenalidomide in Older Patients With Acute Myeloid Leukemia Without Chromosome 5q Abnormalities

Leukemia, Myeloid, Acute

United States
M.D. Anderson Cancer Center
Celgene Corporation

Completed

Revlimid in Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome

Myelodysplastic Syndrome | Acute Myelogenous Leukemia

United States
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate...

Active, not recruiting

A Study to Learn About the Study Medicine (Called Avelumab) in People With Advanced Urothelial Cancer After Chemotherapy

Urothelial Cancer

United Kingdom
M.D. Anderson Cancer Center
Sanofi

Recruiting

Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma Patients

Multiple Myeloma

United States
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

Evaluate the Safety and Efficacy of Tafasitamab Combined With Lenalidomide in Patients With Relapsed or Refractory DLBCL

DLBCL

China
Peking Union Medical College Hospital

Recruiting

Lenalidomide in the Treatment of Mucosal Behçet's Syndrome

Oral Ulcer

China
Seoul National University Hospital

Recruiting

GPL in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma

Relapsed/Refractory Diffuse Large B Cell Lymphoma

Korea, Republic of
Hackensack Meridian Health
Celgene Corporation

Completed

Study of Lenalidomide in Combination With RICE With Lenalidomide Maintenance Post-Auto Transplant for DLBCL (RICER)

Diffuse Large B Cell Lymphoma

United States
Fondazione EMN Italy Onlus

Completed

Safety And Efficacy Of Lenalidomide As Maintenance Therapy In Patients With Newly Diagnosed Multiple Myeloma Following A Tandem Autologous-Allogeneic Transplant

Multiple Myeloma

Italy
Celgene

Completed

Non-interventional Study of Lenalidomide in the Clinical Routine Treatment of TD Patients With IPSS Low or Int-1 MDS and Isolated Del(5q) (PASS MDS del5q)

Myelodysplastic Syndrome

Spain, United Kingdom, Denmark, Germany, France, Greece, Italy, Sweden, Belgium, United States, Luxembourg, Norway
M.D. Anderson Cancer Center

Completed

A Pilot Study to Investigate the Effect of Cytotoxic Therapy and/or Radiotherapy on Cancer Related Sleep Disturbances in CLL and Breast Cancer Patients Experiencing Fatigue

Leukemia | CLL

United States
Celgene

Completed

Lenalidomide Safety/Efficacy in Myelodysplastic Syndromes (MDS) Associated With a Deletion (Del)(5q) Cytogenetic Abnormality

Myelodysplastic Syndromes

United States, Germany
Celgene

Completed

A Multiple-ascending-dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Pomalidomide (CC-4047) in Healthy Male Subjects

Healthy

United States
Celgene
ICON Clinical Research

Completed

Study to Compare the Efficacy and Safety of CC-5013 vs. Placebo in Subjects With Metastatic Malignant Melanoma.

Melanoma | Neoplasm Metastasis

Australia, United Kingdom, Ukraine, Germany, Estonia, Latvia, Lithuania, Netherlands, South Africa
University Hospital, Toulouse
Celgene; Intergroupe Francophone du Myelome

Completed

Maintenance Therapy Using Lenalidomide in Myeloma (IFM2005-02)

Myeloma

France, Belgium, Switzerland
Jason Robert Gotlib
Celgene Corporation

Terminated

Pilot Lenalidomide in Adult Diamond-Blackfan Anemia Patients w/ RBC Transfusion-Dependent Anemia

Leukemia | Anemia | Myelodysplastic Syndromes (MDS) | Acute Myeloid Leukemia (AML)

United States
The Cleveland Clinic
National Cancer Institute (NCI)

Completed

Lenalidomide in Treating Patients With Advanced or Unresectable Kidney Cancer

Kidney Cancer

United States
The Christie NHS Foundation Trust
Celgene Corporation; Leukemia Research Fund

Terminated

RESPeCT: Revlimid Early Stage Poor Prognosis Chronic Lymphocytic Leukaemia (CLL) Trial (RESPeCT)

Chronic Lymphocytic Leukaemia

United Kingdom
Celgene Corporation

Completed

Safety and Efficacy of CC-4047 in Subjects With Metastatic Hormone Refractory Prostate Cancer (HRPC)

Prostate Cancer

United States
Memorial Sloan Kettering Cancer Center
Incyte Corporation

Recruiting

A Study of Tafasitamab and Lenalidomide in People With Mantle Cell Lymphoma

Mantle Cell Lymphoma | MCL

United States
European Myeloma Network
Janssen Pharmaceutica

Recruiting

Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation (MajesTEC-4)

Multiple Myeloma

United Kingdom, Czechia, Australia, Austria, Belgium, Denmark, Germany, Greece, Italy, Netherlands, Norway, Serbia, Switzerland, Turkey, Brazil
Stanford University
Celgene Corporation

Withdrawn

Pomalidomide for Cough in Patients With Idiopathic Pulmonary Fibrosis

Pulmonary Fibrosis

United States
University of Pennsylvania
Celgene Corporation

Completed

Evaluation of Lenalidomide (REVLIMID®) to Treat Subjects With Cutaneous Lupus Erythematosus (CLE)

Cutaneous Lupus Erythematosus (CLE)

United States
University of California, Davis
Celgene

Completed

Study of Lenalidomide in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

Acute Myeloid Leukemia | Myelodysplastic Syndrome

United States
National Cancer Institute (NCI)

Completed

Lenalidomide in Treating Patients With AIDS-Associated Kaposi's Sarcoma

Recurrent Kaposi Sarcoma | AIDS-Related Kaposi Sarcoma

United States
Columbia University
Celgene Corporation

Active, not recruiting

Revlimid in Transfusion Dependent Patients

Myelodysplastic Syndrome

United States
Celgene

Completed

Lenalidomide vs Placebo Maintenance Therapy Following Melphalan Prednisone Velcade® Induction Therapy in NDMM (ARUMM)

Multiple Myeloma

France, Italy, Spain, Belgium, Greece
Mayo Clinic
National Cancer Institute (NCI)

Completed

CC-4047 in Treating Patients With Myelofibrosis

Chronic Myeloproliferative Disorders | Secondary Myelofibrosis

United States
Celgene

Terminated

Efficacy and Safety Study of CC-4047 (Pomalidomide) to Treat Advanced Soft Tissue Sarcoma

Soft Tissue Sarcoma

United States
Celgene

Completed

Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple Myeloma

Multiple Myeloma

Canada, Denmark, Australia, Belgium, France, Germany, Italy, Netherlands, Russian Federation, Spain, Sweden, Switzerland, United Kingdom, Czechia, Greece
Celgene
Prologue Research International

Completed

Study of the Combination of Lenalidomide and DTIC (Dacarbazine) in Patients With Metastatic Malignant Melanoma Previously Untreated With Systemic Chemotherapy

Malignant Melanoma

United States
The Lymphoma Academic Research Organisation
Celgene Corporation

Completed

A Phase IB Study Of The BTKi CC-292 Combined With Lenalidomide In Adults Patients With Relapsed/Refractory B-Cell Lymphoma (CLEAR)

Relapsed/Refractory B-cell Lymphoma

France
Gesellschaft fur Medizinische Innovation - Hamatologie...

Completed

Comparison of 25mg Versus 5 mg Lenalidomide as Maintenance Therapy in Patients With Multiple Myeloma

Multiple Myeloma

Germany
OncoPep, Inc.

Completed

Phase 1/2a Study of Cancer Vaccine to Treat Smoldering Multiple Myeloma

Smoldering Multiple Myeloma

United States
Arbeitsgemeinschaft medikamentoese Tumortherapie
Celgene

Completed

Fludarabine/Rituximab Combined With Escalating Doses of Lenalidomide in Untreated CLL

Chronic Lymphocytic Leukemia | CLL

Austria
Celgene Corporation

Completed

Efficacy and Safety Study of CC-5013 Monotherapy in Subjects With Myelodysplastic Syndromes

Myelodysplastic Syndromes

United States, Denmark, Australia, Belgium, Czech Republic, France, Germany, Greece, Italy, Netherlands, Russian Federation, Spain, Sweden, Switzerland, United Kingdom
M.D. Anderson Cancer Center
Celgene Corporation

Terminated

Lenalidomide (Revlimid) for the Treatment of Refractory Cancer Pain

Pain | Advanced Cancer

United States
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

CC-4047 in Treating Patients With Advanced Solid Tumors That Did Not Respond to Treatment

Unspecified Adult Solid Tumor, Protocol Specific

United States
M.D. Anderson Cancer Center
Celgene Corporation

Completed

Lenalidomide (Revlimid) in Chronic Lymphocytic Leukemia (CLL)

Leukemia | Chronic Lymphocytic Leukemia

United States

Search clinical trials for: Endothelial Growth Factors

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bosnia & Herzegovina

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations